The pharmacokinetics of isradipine, a calcium-channel blocker, have been studied in eight patients on chronic haemodialysis. A single oral dose of 5 mg was administered on both a non-haemodialysis and a haemodialysis day and the plasma concentrations of isradipine were analyzed.
The mean cmax, tmax, AUC, and t1/2 in plasma on the non-haemodialysis day were 5.2 ng·ml−1, 1.4 h, 23.8 ng·h·ml−1, and 3.1 h, respectively. The dialysis clearance of isradipine was negligible (5.0 ml·min−1).
The t1/2 values during haemodialysis were not significantly different from those observed during the same period post dose on the non-haemodialysis day. The study demonstrates that supplemental doses of isradipine are not necessary in these patients since isradipine is not significantly removed by haemodialysis.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Pedersen OL, Krussel LR, Sihn I, Jespersen LT, Thomson K (1988) Long-Term Effects of Isradipine on Blood Pressure and Renal Function. Am J Med 86 [Suppl 4A]: 15–18
Handler CE, Rosenthal E, Tsagadopoulos D, Najn Y (1988) Comparison of Isradipine and Nifedipine in Chronic Stable Angina. Int J Cardiol 18: 15–26
Chandler HH, Schran HF, Cutler RE, Smith AJ, Gonsun LM, Blouin RA (1988) The Effects of Renal Function on the Disposition of Isradipine. J Clin Pharmacol 28: 1076–1080
Jean C, Laplanche R (1988) Assay of Isradipine and of its Major Metabolites in Biological Fluids by Capillary Gas Chromatography and Chemical Ionization Mass Spectrometry. J Chromatogr 428: 61–69
MicroMath Inc, Copyright 1988 RSTRIP, Polyexponential Curve Stripping/Parameter Estimation, Version 3.1
Ching-san CL, Marbury TC (1984) Drug Therapy in Patients Undergoing Haemodialysis. Clinical Pharmacokinetic Considerations. Clin Pharmacokinet 9: 42–66
Gipson TP (1985) Problems in Designing Hemodialysis Drug Studies. Pharmacotherapy 5: 23–29
Abernethy DR, Schwartz JB (1988) Pharmacokinetics of Calcium Antagonists Under Development. Clin Pharmacokinet 15: 1–14
Kleinbloesem CH, van Brummelen P, van de Linde JA, Voogd PJ, Breimer DD (1984) Nifedipine: Kinetics and Dynamics in Healthy Subjects. Clin Pharmacol Ther 35: 742–749
Foster TS, Hamann SR, Richards VR, Bryant PJ, Graves DA, McAllister RG (1983) Nifedipine Kinetics and Bioavailability After Single Intravenous and Oral Doses in Normal Subjects. J Clin Pharmacol 23: 161–170
Kleinbloesem CH, van Brummelen P, Faber H, Danhof M, Vermeulen NPE, Breimer DD (1984) Variability in Nifedipine Pharmacokinetics and Dynamics: A New Oxidation Polymorphism in Man. Biochem Pharmacol 33: 3721–3724
Boelaert J, Valcke Y, Dammekens H, DeVriese G, Ahr G, Schurgers M, Daneels R, Bogaert MG (1988) Pharmacokinetics of Nisoldipine in Renal Dysfunction. Eur J Clin Pharmacol 34: 207–209
Schran HF, Jaffe JM, Gonasun LM (1988) Clinical Pharmacokinetics of Isradipine. Am J Med 84 [Suppl 3B]: 80–89
Follath F, Taeschner W (1988) Clinical Pharmacology of Calcium Antagonists. J Cardiovasc Pharmacol 12 [Suppl 6]: S98-S100
Hanyok JJ, Chow MSS, Kluger J, Izard MW (1988) An Evaluation of Pharmacokinetics, Pharmacodynamics and Dialyzability of Verapamil in Chronic Hemodialysis Patients. J Clin Pharmacol 28: 831–836
About this article
Cite this article
Schönholzer, K., Marone, C. Pharmacokinetics and dialysability of isradipine in chronic haemodialysis patients. Eur J Clin Pharmacol 42, 231–233 (1992). https://doi.org/10.1007/BF00278492